ARS Pharmaceuticals, Inc. SPRY R2KR3KPHARMA
Company Overview
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 97.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $84.28M (-5.5% YoY); net profit $-171.30M.
- Trailing 12 Months Year-on-year growth — revenue +114.2%, earnings -2241.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 97.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 97.80% |
| 1 Year: | 114.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -2,241.76% |
Stock Price Performance
| 1 Year: | -74.53% |
| 6 Months: | -51.39% |
| 3 Months: | -30.03% |
| 1 Month: | -2.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.39 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 97.8% over 5 years.
CONS
- Trading 74.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPRY ARS Pharmaceuticals, Inc. R2KR3KPHARMA | 4.03 | -1.85 | $400.77M | 0.00% | -62.20% | - | 97.80% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 663.00K | 464.00K | 189.00K | 20.00K | 10.00K | 0 | 0 | 500.00K | 2.07M | 7.97M | 15.72M | 32.50M | 22.68M |
| Operating Income | -5.24M | -6.46M | -8.11M | -18.89M | -24.51M | -22.68M | -7.10M | -6.34M | -6.63M | -18.71M | -20.60M | -17.98M | -13.19M | -15.34M | -21.75M | -37.18M | -47.61M | -53.19M | -60.15M |
| Net Income | -5.28M | -6.47M | -8.12M | -18.87M | -24.50M | -22.66M | -7.25M | -6.42M | -6.58M | -14.96M | -17.37M | -14.87M | -10.29M | -12.52M | -19.13M | -33.94M | -44.88M | -51.15M | -60.62M |
| Diluted EPS | - | - | - | - | - | -0.65 | -0.24 | -0.21 | -0.21 | -0.16 | -0.18 | -0.16 | -0.11 | -0.13 | -0.20 | -0.35 | -0.46 | -0.52 | -0.61 |
| R&D Expense | 4.41M | 5.13M | 6.20M | 12.24M | 17.75M | 15.64M | 5.42M | 4.35M | 3.89M | 6.55M | 7.31M | 3.00M | 5.23M | 6.90M | 4.42M | 2.95M | 4.04M | 2.75M | 4.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 5.51M | 1.32M | 30.00K | 89.15M | 84.28M |
| Operating Income | -32.92M | -19.45M | -35.52M | -67.52M | -3.08M | -179.45M |
| Net Income | -32.95M | -20.24M | -34.68M | -54.37M | 8.00M | -171.30M |
| Diluted EPS | - | -0.70 | -0.87 | -0.57 | 0.08 | -1.74 |
| R&D Expense | 24.58M | 20.27M | 18.38M | 20.27M | 19.58M | 13.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 394.80M | 61.45M | 281.44M | 233.19M | 351.15M | 327.65M |
| Total Equity | -58.78M | -14.05M | -31.27M | 272.89M | 230.76M | 256.80M | 114.26M |
| Cash & Equivalents | - | 386.57M | 60.06M | 210.52M | 70.97M | 50.82M | 41.32M |
| Long Term Debt | - | - | - | - | - | 0 | 96.37M |
| Total Liabilities | - | 11.93M | 16.68M | 8.55M | 2.43M | 94.36M | 213.39M |
| Current Liabilities | - | 9.60M | 8.19M | 5.44M | 2.39M | 23.44M | 39.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.20M | -17.56M | -40.08M | -59.27M | 13.55M | -170.87M |
| Investing Cash Flow | -917.00K | -55.00K | -199.00K | -87.18M | -106.10M | 56.77M |
| Financing Cash Flow | 408.51M | 53.16M | 190.73M | 6.90M | 72.40M | 104.60M |
| Capital Expenditure | -917.00K | -55.00K | -199.00K | -175.00K | -563.00K | -339.00K |
| Free Cash Flow | -32.11M | -17.62M | -40.28M | -59.44M | 12.98M | -171.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | -353.3% | -2,698.8% | -225,066.7% | -3.5% | -212.9% |
| Net Margin % | - | -367.7% | -2,635.4% | -181,216.7% | 9.0% | -203.3% |
| ROE % | 234.5% | 64.7% | -12.7% | -23.6% | 3.1% | -149.9% |
| ROCE % | -8.5% | -36.5% | -12.9% | -29.3% | -0.9% | -62.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 10.92% | 10.86M | $45.94M |
| 2 | Rubric Capital Management LP | 8.59% | 8.54M | $36.13M |
| 3 | Orbimed Advisors LLC. | 8.33% | 8.29M | $35.06M |
| 4 | Deerfield Management Company, L.P | 7.55% | 7.50M | $31.74M |
| 5 | Blackrock Inc. | 5.34% | 5.31M | $22.47M |
| 6 | Tyro Capital Management LLC | 4.48% | 4.46M | $18.86M |
| 7 | Aberdeen Group plc | 4.19% | 4.17M | $17.64M |
| 8 | SR One Capital Management, LP | 4.04% | 4.01M | $16.97M |
| 9 | State Street Corporation | 3.75% | 3.73M | $15.78M |
| 10 | Capital World Investors | 2.77% | 2.75M | $11.65M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPRY
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOLU1lMWV4RWdTbGQzeVFvNW94ekE1NjU2UE5scVRLNXlJYlhZdDctUUFScXNhYmhKRkJnSVFoOUkzLWJJcFM0TFphbW9OVEE1VXFlWVB0UU9LN3R6TjBKX2NZckFVUGw2emc1NG50OVlMT1BMVzdyVEJxZERsbUZqWTYyeGkzeGx6a1FqLX…
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxNdXlzNnZ2OEtIU01tYzBDLXJEX3Z5ejBhMkRoSXlHd1pvVG9ZcUc3a1QtcWFiWDZkeC1QdXhjejRMSlVBb0RTMWtwdDVsYlVfV0VfUnJvQnlqYUhKdnkzTTNBZF9qOHlRcjZSQ0Rfd1Bud2lJUWZvTEpwVEd6UFBOMlNtZ0xoUGJXY2F1Tm…
SPRY Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE0zNmlCWFZFTHhiZzJxUDUtb1d5TFpkLURnbWllSXFCdWZvcUJEaTZ4SERFQTh5WGFIRTZDamZ3MkI0U3h2cFhqYm1mcVZjdE5wd3lqSmtkd1RIdGNqWkZxVUtwSHo5Uk5mYjBXb0lQOGFoUnlGY0JqTW9n?oc=5" target="_blank">SPR…
ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage - Benzinga
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPMllwYk5oMHVkQVRybFZaYmxtbU5kWFhjZlg5Q2RZSm5hRFY1NFh4Y0JPVzdEUHZjNGVzTFllOXZRRElZcUFjSUVVLWFMd3EyZmlUaFFma19tX2NubXF1UERxRHpZZWUybVZvVU5tQ1lFcEJSb3NOZ3ZfQ0VfejU1d2NRX0ZRWEh0RFNhRE…
ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOTWg1Mkw1XzBPa290RkkwdGZrTXRMSHNaQ2ZPWkVvVEJLdGZodjFDeTVvNjVKWFVCaTBwUkprTncySE1RZlhWWjMwVFB3SkRnVksyVFQwWUZGMFhTaVJaNmJHRTdzeUNIYU1IRGlmMjJBMFZGcUhhRTUtaHlWQi15NzUxTnpXb0ZPWG4tNG…
ARS Pharmaceuticals (NasdaqGM:SPRY) Stock Forecast & Analyst Predictions - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNMlNSXzVtbG1CUl8wTWdLMlI0YjV1bzZJVzh3VnItakFfanJTTXlrYWxITHVzRzRhY3prMXBQVEE1b2RQczg5Vk4zcEVsZHNpLWczYk1HLXF2cmg4MmdMRS1TT3prMDVaTWloUWUyNFJ4ZzNUVUp2N05USGJEcFJLSHlhcDJ2Z0RtTFl1an…
SPRY — Frequently Asked Questions
What is the current share price of ARS Pharmaceuticals, Inc. (SPRY)?
As of 2026-10-23 16:27 PDT, ARS Pharmaceuticals, Inc. (SPRY) trades at $4.03 on NasdaqGM. Its 52-week range is $3.93 to $15.82.
What is the market capitalisation of SPRY?
ARS Pharmaceuticals, Inc. (SPRY) has a market capitalisation of $400.77M on NasdaqGM.
What is the P/E ratio of SPRY?
SPRY trades at a trailing price-to-earnings (P/E) ratio of -1.85. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 32.62.
Is SPRY a good stock to buy?
This page provides a data-driven analysis of ARS Pharmaceuticals, Inc. (SPRY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.